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Purpose: We sought to report outcomes and toxicity in patients with hepatocellular 
carcinoma (HCC) who received resin yttrium-90 selective internal radiation therapy 
(90Y-SIRT) and to identify factors associated with declining liver function.
Methods: Patients treated with 90Y-SIRT were retrospectively evaluated. Radiographic 
response was assessed using RECIST 1.1. Median liver progression-free survival (LPFS) 
and overall survival (OS) were calculated using the Kaplan–Meier method. Bivariate 
analysis was used to examine associations between change in Child-Pugh (CP) score/
class and patient characteristics and treatment parameters.
results: Twenty-seven patients with unresectable HCC underwent SIRT, 52% were CP 
Class A, 48% were Class B, 11% were BCLC stage B, and 89% were stage C. Forty-four 
percent of patients had portal vein thrombus at baseline. One-third of patients received 
bilobar treatment. Median activity was 32.1  mCi (range 9.18–43.25) and median- 
absorbed dose to the liver was 39.6 Gy (range 13.54–67.70). Median LPFS and OS were 
2.5 and 11.7 months, respectively. Three-month disease control rate was 63 and 52% 
in the target lesions and whole liver, respectively. New onset or worsened from baseline 
clinical toxicities were confined to Grade 1–2 events. However, new or worsened Grade 
3–4 laboratory toxicities occurred in 38% of patients at 3 months and 43% of patients 
at 6 months following SIRT (six had lymphocytopenia, three had hypoalbuminemia, and 
two had transaminasemia). After 3 months, six patients had worsened in CP score and 
five had worsened in class from baseline. After 6 months, four patients had worsened in 
CP score and one had worsened in class from baseline. Pretreatment bilirubinemia was 
associated with a 2+ increase in CP score within 3 months (P = 0.001) and 6 months 
(P = 0.039) of 90Y-SIRT. Pretreatment transaminasemia and bilirubinemia were associated 
with increased CP class within 3 months of SIRT (P = 0.021 and 0.009, respectively).
conclusion: 90Y-SIRT was well-tolerated in patients with unresectable HCC, with no 
Grade 3–4 clinical toxicities. However, Grade 3–4 laboratory toxicities and worsened CP 
scores were more frequent. HCC patients with pretreatment bilirubinemia or transami-
nasemia may be at higher risk of experiencing a decline in liver function following 90Y-SIRT.
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inTrODUcTiOn
Hepatocellular carcinoma (HCC) is the sixth most common 
malignancy worldwide and the second most common cause 
of cancer-related mortality (1). Transplantation and surgical 
resection are potentially curative options but only 30–40% of the 
patients are amenable to curative treatment at diagnosis (2). As 
most patients are not eligible for curative treatment they must 
rely on systemic and locoregional therapies. Systemic therapies, 
such as sorafenib, a multi-targeted small molecule tyrosine 
kinase inhibitor, have demonstrated comparatively modest but 
still poor survival improvements of 2–3 months in patients with 
advanced HCC who are not candidates for transplant or resec-
tion (3). However, the response rate on sorafenib is <5% and all 
initially responding patients eventually develop resistance (3). 
Locoregional therapies for HCC can have a significant impact on 
the course of the disease, since many patients die of progressive 
disease (PD) within the liver. While external radiation therapy is 
an option for selected patients, this technique is often limited by 
the tolerance of the normal liver parenchyma.
Selective internal radiation therapy is emerging as an important 
locoregional modality in the treatment of metastatic and primary 
liver tumors. The treatment involves intra-arterial administration 
of resin or glass microspheres containing beta-emitting 90Y that 
preferentially accumulate in liver tumors and deliver cytotoxic 
doses of radiation (4). This technique exploits the liver’s unique 
vasculature system in which liver tumors derive up to 90% of their 
blood supply from the hepatic artery, while normal liver paren-
chyma is predominantly supplied by the portal venous system (5).
Multiple studies have demonstrated the feasibility and 
tolerability of 90Y SIRT for the treatment of liver metastasis and 
primary liver tumors (6–10). SIRT is often associated with mild 
toxicities in the first several days following treatment, includ-
ing nausea, vomiting, fatigue, abdominal pain, and fever (8, 9). 
Serious adverse events, including radiation pneumonitis and 
gastric ulceration resulting from radiation applied to non-target 
tissues, are rare (10). While transient changes in liver function 
tests following SIRT are common, radiation-induced liver dys-
function (RILD) or liver failure is reported in <5% of patients 
(11). Classic RILD is defined as anicteric hepatomegaly, ascites, 
and elevated alkaline phosphatase (ALP) occurring 2  weeks to 
4 months after radiation therapy (12).
Unlike patients with metastatic disease to the liver, many 
patients with HCC and cirrhosis have preexisting liver dysfunc-
tion, which may predispose them to toxicity following SIRT. The 
purpose of this study is to report outcomes and evaluate clinical 
and laboratory toxicities in patients with HCC treated with 90Y 
resin SIRT. In addition, we seek to identify predictive markers 
associated with the development of worsening hepatic function 
following SIRT.
MaTerials anD MeThODs
Patient cohort
Twenty-seven patients with primary, unresectable HCC treated 
with 90Y SIRT at the MedStar Georgetown University Hospital, 
Washington, DC, USA, between February 2012 and September 
2014 were evaluated. A comprehensive review of imaging stud-
ies, survival outcomes, and clinical toxicities was performed, and 
data were collected retrospectively. A secure HIPAA-compliant 
database was constructed for the management of patient data. 
The MedStar/Georgetown Institutional Review Board approved 
the ethical, legal, and social implications of the study.
Pretreatment evaluation and Patient 
selection
All patients underwent pretreatment evaluations, including clinical 
history and physical examination, as well as laboratory and imag-
ing baseline assessments. Eligible patients had a biopsy confirmed 
or radiographic diagnosis of HCC that was deemed surgically 
unresectable due to tumor location and/or bulk, and not amenable 
to liver transplant. Patients had to be at least 18 years old, have an 
Eastern Cooperative Oncology Group (ECOG) score of 0 or 1, 
and have a life expectancy of >3 months. Patients were excluded 
for inadequate liver function (Grade 2+ ascites, serum albumin 
<3.0  g/dL, and total bilirubin >2.0  mg/dL), radiation exposure 
to the lungs of >30 Gy in a single fraction or 50 Gy in multiple 
administrations, and uncorrectable flow of 90Y microspheres to the 
gastrointestinal tract. The presence of portal vein thrombus and/or 
extrahepatic metastasis was not considered exclusionary.
sirT Planning and Procedure
All patients were treated with resin 90Y microspheres. The 
details for the procedure can be found in the 2013 version of 
the SIR-Spheres® product insert and in Kennedy et al. (13, 14). 
A pretreatment diagnostic angiogram was performed in all 
patients, and specific extrahepatic vessels were coil embolized 
to prevent 90Y-microspheres from being distributed into visceral 
organs other than the liver during the SIRT procedure. Arteries 
that were actively sought and embolized included the gastroduo-
denal artery, the right gastric artery, the pancreaticoduodenal 
vessels, and any other relevant arteries depending on the patient-
specific anatomy. A technetium-99m macroaggregated albumin 
(99m-Tc-MAA) SPECT scan was performed to calculate the lung 
shunt fraction, and a dose reduction was applied to maintain 
a lung radiation dose below 30  Gy. The prescribed activity of 
 microspheres to be delivered was calculated using body surface 
area (BSA) method, which incorporates BSA, liver lobe vol-
ume, and percent tumor involvement of the lobe into the dose 
calculation (14). If stasis was achieved prior to full delivery of 
the prescribed dose of microspheres, the infusion was stopped 
and the dose delivered was recorded. A post-embolization 
Bremsstrahlung SPECT scan was performed to confirm the loca-
tion of microsphere delivery.
Toxicity assessment
Patients typically underwent outpatient follow-up at 1  week, 1, 
and 3 months after 90Y SIRT, and then every 3 months thereafter 
until death. At these visits, physical examination and laboratory 
tests were performed. The following laboratory parameters were 
included in our analyses in order to assess laboratory toxicity: 
total bilirubin, ALP, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), albumin, hemoglobin (HGB), and 
TaBle 1 | Baseline characteristics.
characteristic Patients (%)
Age (median, min–max) 62.2 (39–85)
Sex [n (%)]
 Female 7 (26)
 Male 20 (74)
ECOG performance status
 0 6 (22)
 1 17 (63)
 2 2 (7)
 Unreported 2 (7)
Comorbidities
 Hypertension 25 (93)
 Ascites 19 (70)
 Liver cirrhosis 19 (70)
 Hepatitis C infection 17 (63)
 Diabetes mellitus type II 15 (55)
 Coronary artery disease 5 (19)
 Hepatitis B infection 5 (19)
Child-Pugh score
 5A–6A 14 (52)
 7B–9B 13 (48)
BCLC stage
 B 3 (11)
 C 24 (89)
Extrahepatic metastasis
 Yes 8 (30)
 No 18 (66)
 Unreported 1 (4)
Portal vein thrombus
 Yes 12 (44)
 No 15 (56)
Prior systemic treatment
 Sorafenib 21 (78)
 5-Flurouracil + oxaliplatin 1 (4)
 Gemcitabine + cisplatin 1 (4)
Subsequent locoregional therapy
 TACE 9 (33)
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lymphocytes. Blood samples taken up to 4 weeks prior to 90Y SIRT 
and at 3, 6  months, and 1  year during posttreatment follow-up 
were used for toxicity analysis. Clinical and laboratory toxicities 
were graded according to the Common Terminology Criteria 
for Adverse Events (CTCAE) v4.03. If baseline and follow-up 
laboratory data were not available for any particular patient in 
the chosen cohort, this patient was excluded from the laboratory 
toxicity assessment. Clinical toxicity assessment was based on 
the reporting in patients’ charts of periprocedural complications, 
treatment-related symptoms (CTCAE Grade 1–2), and serious 
adverse events (CTCAE Grade 3–4). Laboratory and clinical 
toxicities noted following radiographically confirmed progression 
of disease or subsequent locoregional therapy were excluded from 
analyses.
Child-Pugh (CP) score was used to assess changes in liver 
function after SIRT. An increase in CP score by two or more 
points was deemed to be a clinically relevant indicator of decline 
in liver function following radiotherapy in one prior analysis 
(15). For data analysis purposes, changes in liver function were 
expressed as a binary value at 3 and 6 months post-SIRT: patients 
with a 2+ increase in CP score from baseline were given a 1 at 
each follow-up point; those with a score increase of <2 were 
given a 0. The observation of clinical/laboratory toxicities and a 
2+ point increase in CP score in the absence of HCC progression 
and subsequent locoregional therapy were considered treatment 
related and were the focus of our analyses.
sirT response assessment
Baseline imaging of the liver was performed using either CT or 
MRI techniques. The choice of follow-up imaging methodology 
was the same as that used for baseline imaging and occurred at 
approximately 3 posttreatment. Response assessment was per-
formed in accordance with the Modified Response Evaluation 
Criteria in Solid Tumors version 1.1 (RECIST 1.1) on the level 
of target lesions and whole liver (includes non-target and new 
lesions) at 3 months after SIRT.
statistical analysis
Liver progression-free survival (LPFS) and overall survival (OS) 
were calculated using Kaplan–Meier survival analyses and were 
calculated from the first 90Y SIRT treatment. Bivariate analyses 
were used to examine the association of CP score/class with 
patient characteristics and treatment parameters. Statistical 
analyses were performed using SPSS Statistics 21.0 for Windows 
(IBM SPSS, Chicago, IL, USA); P < 0.05 was considered statisti-
cally significant.
resUlTs
Patient Demographics
The demographic and baseline characteristics of study patients 
are shown in Table 1. The mean age was 62.2 (range, 39–85) and 
the majority (74%) were male. At baseline, most patients (85%) 
had an ECOG performance status of 0 or 1, and only 30% had 
extrahepatic metastasis. Twelve patients (44%) had tumor portal 
vein thrombus, according to baseline scans, and pretreatment 
liver function assessment showed an equal number of patients 
with CP A (52%) and CP B disease (48%). Pretreatment BCLC 
staging identified 3 patients (11%) as BCLC stage B and 24 
patients (89%) as BCLC stage C. The most common comorbidi-
ties were hypertension (93%, n = 25), ascites (70%, n = 19), liver 
cirrhosis (70%, n = 19), hepatitis C viral infection (63%, n = 17), 
and diabetes mellitus type II (55%, n = 15). Twenty-three patients 
(85%) had received prior systemic therapy. Twenty-one patients 
(78%) were treated with sorafenib, one patient (4%) was treated 
with combination 5-flurouracil and oxaliplatin, and one patient 
(4%) was treated with combination gemcitabine and cisplatin 
prior to SIRT.
Treatment Details
Treatment information is shown in Table 2. One-third of patients 
(n =  9) received bilobar treatment, with no patients receiving 
treatment of both lobes on the same day. The mean lung shunt 
fraction was 6.52% and six patients (22%) received a reduced 
dose at the discretion of the treating physicians. The median 
administered radioactivity was 32.1  mCi (range 9.18–43.25) 
TaBle 2 | sirT treatment details.
Treatment variable
99mTc-MAA lung shunt fraction (mean) 6.52%
Dose reduction required in “n” patients 6 (20%)
Mean 90Y administered activity (MBq) 1185 ± 340
Mean 90Y liver-absorbed dose (Gy) 39.6 ± 13.1
Number of patients with concurrent 90Y treatment and 
chemotherapy (n)
7 (23%)
Patients receiving bilobar treatment (n) 9 (30%)
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with an estimated median liver-absorbed dose of 39.6 Gy (range 
13.54–67.7). No periprocedural complications occurred during 
90Y microsphere administration. There were no instances of 
extrahepatic deposition of radioactivity based on posttreatment 
bremsstrahlung scintigraphy.
Toxicities
Median follow-up time was 10.1  months (range 0.6–29.6). 
Twenty-three patients were included in the toxicity analysis; four 
patients (15%) in our cohort were excluded due to incomplete 
laboratory data or inappropriate timing of laboratory follow-up 
for our study. Laboratory toxicities occurring at 3, 6 months, and 
1 year after SIRT were classified by CTCAE Grade and summa-
rized in Figure 1. The number of patients at risk of developing 
Grade 3 or 4 laboratory toxicities at 3 and 6 months after SIRT 
was 16 and 7, respectively, after excluding patients who had 
PD in the liver or received additional liver directed therapy. At 
3 months after SIRT, 6 out of 16 patients at risk (38%) suffered 
new onset or worsened from baseline Grade 3 or 4 laboratory 
toxicities: 4 patients (25%) had lymphocytopenia, 1 patient (6%) 
had hypoalbuminemia, and 1 patient had transaminasemia. At 
6  months after SIRT, three out of seven patients at risk (43%) 
suffered new onset or worsened from baseline Grade 3 or 4 labo-
ratory toxicities: two patients (29%) had lymphocytopenia, and 
one patient had hypoalbuminemia. All other laboratory toxicities 
were limited to Grade 1–2 events.
Clinical toxicities occurring within 1 year of SIRT are sum-
marized in Table 3. New onset or worsened from baseline clinical 
toxicities were confined to Grade 1 or 2 events. Many of these 
symptoms were associated with post-embolization syndrome, 
which resolved before the first 3 months of follow-up. No Grade 
3 or 4 clinical toxicities were observed after yttrium-90 selective 
internal radiation therapy (90Y-SIRT) and no radiation-induced 
complications, such as gastrointestinal ulceration, pulmonary 
toxicity, pancreatitis, or radiation pneumonitis, were observed.
liver Function assessment
After 3 months, 6 out of 16 patients at risk (38%) had experienced 
an increase in CP score and 5 (32%) showed an increase in CP 
class. After 6 months of follow-up, four out of seven patients at 
risk (57%) had an increased CP score and one (14%) showed an 
increase in CP class. An increase of at least 2 points in the CP score 
was noted in nine patients (39%) during the 1-year follow-up 
period. Among these nine patients, two patients (22%) recovered 
from the CP score increase within 6 months of SIRT treatment.
Tumor response and survival
Tumor response to therapy at both the target lesion and whole 
liver level were analyzed according to RECIST 1.1 criteria at 
3  months (range, 1.5–4) following 90Y SIRT (Table  4). Three 
patients (11%) were excluded from radiographic analysis due 
to lack of evaluable imaging or change in imaging modality. 
At 3  months posttreatment, the disease control rate [complete 
response (CR) + partial response (PR) + stable disease (SD)] was 
63% for target lesions and 52% for the whole liver. Seven patients 
(26%) had PD for the target lesions and 10 patients (37%) had 
PD of the whole liver after 3 months posttreatment. Nine patients 
(33%) received subsequent locoregional therapy (trans-arterial 
chemoembolization) following SIRT.
Median LPFS and OS for the entire cohort were 2.5 months 
(95% CI 1.9–3.1) (Figure 2) and 11.7 months (95% CI 6.6–16.8) 
(Figure 3), respectively. In the absence of a 2+ increase in CP 
score within the first 6 months of follow-up, median LPFS was 
2.5 months (95% CI 1.8–3.2) and median OS was 11.85 months 
(95% CI 7.7–14.3); patients who experienced a 2+ increase in CP 
score within the first 6 months of follow-up had a median LPFS 
of 2.3 months (95% CI 1.3–3.2) and median OS of 8 months (95% 
CI 1.6–14.4) (Figures 4 and 5).
association Between laboratory/
Treatment Parameters and Decline in liver 
Function Following sirT
Bivariate analyses were used to assess the association between 
baseline laboratory/treatment parameters and postoperative 
decline in liver function, as defined by a 2+ increase in CP 
score or 1+ increase in CP class. Bivariate analyses showed that 
pretreatment bilirubinemia was associated with a 2+ increase in 
CP score within 3 months (P = 0.001) and 6 months (P = 0.039) 
of SIRT. Pretreatment bilirubinemia and transaminasemia were 
associated with an increase in CP class within 3 months of SIRT 
(P = 0.021, 0.028, and 0.009, respectively). The following pretreat-
ment factors were not significantly related with a decline in post-
treatment liver function: ALP, albumin, HGB, CP class, model for 
end-stage liver disease (MELD) score, BCLC stage, portal vein 
thrombus at baseline, radioactivity, dose, and bilobar treatment.
DiscUssiOn
Hepatocellular carcinoma is one of the most common forms of 
cancer worldwide, remaining the second leading cause of cancer-
related death in men and the sixth leading cause in women (16). 
For many HCC patients, curative resection or transplantation is 
not an option due to tumor bulk or the presence of metastatic 
disease. Locoregional therapies, such as 90Y-SIRT, are a viable 
alternative method of reducing tumor burden, prolonging OS, 
and improving quality of life.
Our study has demonstrated that resin 90Y-SIRT is a well-
tolerated treatment option for patients with primary unresectable 
HCC. Similar to previously published studies, clinical toxicities in 
the current study were limited to Grade 1 and 2 events, primarily 
those associated with post-embolization syndrome (17–19). The 
majority of these symptoms resolved within the first 3 months of 
ALP AST ALT Albumin Total Bilirubin HGB Lymph
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
BL 3m 6m 1yr BL 3m 6m 1yr BL 3m 6m 1yr BL 3m 6m 1yr BL 3m 6m 1yr BL 3m 6m 1yr BL 3m 6m 1yr
Grade 1 Grade 2 Grade 3 Grade 4
FigUre 1 | Bar chart demonstrating the incidence of laboratory toxicities at baseline visit (Bl) and 3, 6 months, and 1 year after sirT. Laboratory 
parameters included alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, total bilirubin, hemoglobin (HGB), and 
lymphocytes (Lymph). Toxicities were classified by CTCAE Grade: blue = Grade 1, green = Grade 2, yellow = Grade 3, and red = Grade 4.
TaBle 4 | Tumor response to sirT at the target lesion and whole-liver 
level after 3 months of follow-up.
Target lesions Whole liver
Complete response 0 (0%) 0 (0%)
Partial response 1 (4%) 1 (4%)
Stable disease 16 (59%) 13 (48%)
Progressive disease 7 (26%) 10 (37%)
Not evaluable 3 (11%) 3 (11%)
Disease control rate 63% 52%
TaBle 3 | clinical toxicities following sirT.
grade 1 or 2 adverse events Patients (%)
Abdominal pain 23 (85)
Fatigue 22 (81)
Ascites 18 (67)
Nausea 12 (44)
Diarrhea 10 (37)
Vomiting 7 (26)
Hepatic encephalopathy 5 (19)
Fever 3 (11)
Jaundice 3 (11)
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follow-up after SIRT. Particularly deleterious clinical toxicities, 
such as gastrointestinal ulceration and radiation pneumonitis, 
were not observed in this study, likely due to careful patient 
selection and pretreatment diagnostic work-up. The other main 
safety consideration in this SIRT cohort was hepatotoxicity due to 
unintentional but unavoidable irradiation of benign liver tissue. 
Previous studies demonstrated that up to 70% of patients develop 
low-grade (Grade 1–2) abnormal liver function tests following 
SIRT (20–22), and the incidence of high-grade (Grade 3–4) 
laboratory toxicities has been reported to range from 0 to 38% (7, 
20, 23, 24). In the current study, 65% (n = 15) and 39% (n = 9) of 
patients experienced Grade 1–2 and Grade 3 laboratory toxicities, 
respectively, within 6  months of follow-up. The most frequent 
Grade 3 toxicities were lymphocytopenia and hypoalbuminemia. 
No Grade 4 toxicities were observed.
According to recent studies, 3-month disease control rates 
following 90Y-SIRT in patients with advanced HCC range from 
56 to 100% when evaluated using RECIST criteria (9, 25–27). The 
tumor response in the current study yielded comparable results: 
3-month disease control rate was 63% in the target lesions and 
52% in the whole liver. The median LPFS (2.5 months) and OS 
(11.7  months) observed in this study are comparable with the 
LPFS and OS observed in a number of studies examining the clini-
cal benefit of 90Y-SIRT in patients with advanced HCC (28–32).
The risk of liver toxicity is an important consideration fol-
lowing SIRT (17, 33–35). Previous studies have attempted to 
identify radiographic and dosimetric predictors of liver toxic-
ity; the percentage of liver volume receiving more than 30 Gy, 
percentage of lung volume receiving more than 20 Gy, pretreat-
ment hepatopulmonary shunt fraction, and pretreatment liver 
cirrhosis have all been independently associated with liver 
toxicity following SIRT (36–42). A recent report demonstrated 
that a 2+ change in CP score is a clinically important indicator of 
decline in liver function and survival in patients with unresect-
able HCC who have received radiotherapy (15). This finding is 
supported by the survival data in our current study. Patients who 
did not develop a 2+ increase in CP score had prolonged LPFS 
(0.2 months longer) and OS (3.4 months longer) when compared 
with patients who did.
FigUre 2 | Kaplan–Meier curve of lPFs in patients receiving sirT.
FigUre 3 | Kaplan–Meier curve of Os in patients receiving sirT.
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It has been suggested that HGB level prior to SIRT may be 
an important laboratory marker for tumor response and liver 
function in patients with liver metastases (43). To date, no 
studies have demonstrated an association between pretreatment 
laboratory values and liver toxicity following SIRT in primary 
HCC. In order to identify predictive markers of liver toxicity 
following SIRT in our cohort, patient baseline laboratory values 
and treatment parameters were correlated with the observed 
changes in CP score and class. Our analysis revealed a statisti-
cally significant association between pretreatment bilirubinemia 
FigUre 4 | Kaplan–Meier curves comparing Os in patients with or without a 2+ increase in cP score.
FigUre 5 | Kaplan–Meier curves comparing lPFs in patients with or without a 2+ increase.
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